Discovery of epidermal/dermal targeting formulations for cutaneous squamous cell carcinoma - the incidence and mortality rates of cutaneous squamous cell carcinoma (CSCC) and skin cancer continues…

Ended Project Grant Awarded Last action

Award ID
R43CA257783
Recipient
Awarding agency
Obligated
$755,751

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date
Originally
Funding
  • $503,834.00 Federal
  • $251,917.00 Non-federal
Place of performance
Austin, TX 78750, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Discovery of epidermal/dermal targeting formulations for cutaneous squamous cell carcinoma - the incidence and mortality rates of cutaneous squamous cell carcinoma (CSCC) and skin cancer continues to increase. IT is expected that 1 in 5 americans will develop skin cancer in their lifetime. Although surgical excision is typically indicated and effective, surgery is not always appropriate or possible. Efforts to treat and/or prevent using pharmacological agents are limited by poor delivery to the site of action (the skin epidermis and dermis) and majority of the pharmacological therapy involves systemic administration with few topical agents available. Existing drugs and combinations of natural compounds with potential to be used against skin cancer, including CSCC, have

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $251,917 $0
Original award $251,917 $251,917

Quick answers

Who received award R43CA257783?

R43CA257783 was awarded to Via Therapeutics, LLC by National Cancer Institute (National Institutes of Health) on July 12, 2021.

How much is award R43CA257783 worth?

$755,751 has been obligated on R43CA257783: $503,834 in federal funding and $251,917 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login